DRG Successful Exhibit at ENDO Expo 2016!

Sep 5, 2016 | Events | 0 comments

DRG International, Inc. recently exhibited at ENDO EXPO 2016, the largest meeting of endocrine practitioners and researchers, from April 1 – 3 at the Boston Convention & Exhibition Center in Boston, MA. A highlight at the show was DRG’s new Hepcidin-25 Bioactive High-Sensitive (HS) kit, EIA5782, which is now for sale. You can learn more about our Hepcidin product here.

Michael V. Martini III, Director of Sales & Marketing, at the DRG International, Inc. Booth.

Michael V. Martini III, Director of Sales & Marketing, at the DRG International, Inc. Booth.

In addition to the presentation of several new assays DRG offered live demonstrations of our fully automated continuous access analyzer: DRG:HYBRiD-XL®. Visitors from around the world gathered to receive personalized presentations of the Hybrid-XL instrument. DRG’s Salivary Assay ELISA product line was also a big attraction at the conference, especially as DRG is preparing to launch a new, re-optimized line of salivary assays. You can find more information on DRG Salivary Assay ELISA kits here.

A DRG:Hybrid-XL Fully Automated Immunoassay and Clinical Chemistry Analyzer at the DRG Booth

A DRG:Hybrid-XL Fully Automated Immunoassay and Clinical Chemistry Analyzer at the DRG Booth

Gregory C. Guest

Gregory C. Guest

Gregory C. Guest is the International Marketing Manager located at DRG International’s worldwide headquarters in Springfield, NJ.
Gregory C. Guest

News and Updates

Sign Up for Our Newsletter

  • By submitting this form, you are granting: DRG International, Inc., 841 Mountain Avenue, Springfield, NJ, 07081, permission to email you. You may unsubscribe via the link found at the bottom of every email. (See our Email Privacy Policy (http://constantcontact.com/legal/privacy-statement) for details.) Emails are serviced by Constant Contact.

Click the link to learn more about how DRG is certified in the manufacturing and distribution of in-vitro diagnostic reagents used in the diagnosis of autoimmune status, cancer, cardiac markers, disease status, fertility testing, pregnancy testing, diabetes and immune status.